Nova Pharmaceutical Inc. Announces Agreement with Hawthorne Direct, Inc. For NxTrim Direct Marketing Campaign|
LAKE ELSINORE, Calif., March 2 /PRNewswire/ -- Nova Pharmaceutical Inc. (OTC Bulletin Board: NOVX) has signed a direct marketing agreement with the nation's first infomercial ad agency, Hawthorne Direct, Inc. The agreement entails the production and airing of a thirty-minute direct response infomercial for Nova's flagship product NxTrim.
Hawthorne, based in Farfield Iowa, has managed over 350 infomercial campaigns, with companies such as Apple Computer, Bank of America, Jenny Craig, and Slim Fast. Hawthorne Direct is responsible for the creative and production for Nova Pharmaceutical's infomercial, introducing the Company's NxTrim product to the DRTV audience.
NxTrim is a natural dietary supplement that was launched by Nova Pharmaceutical Inc. in February of 1998. Today, the product is distributed in over 11,000 locations in the U.S., including Albertsons/American Stores, Inc., Rite Aid, and Longs Drug. According to the most recent report released by Information Resources Inc., NxTrim is ranked number one in its class in the California Drug market. Nova's CEO, Ralph Mann, is confident that the successful performance of NxTrim through retail channels will reflect in the infomercial. "NxTrim is a proven seller, and is also proven to deliver results," says Mr. Mann. The Company conducted a 90-day double blind clinical study. Results indicated that subjects who used NxTrim in conjunction with a prescribed exercise and healthy eating plan, lost an average of 27 pounds with no adverse side-effects. The placebo group involved in the study, which used a multi-vitamin, lost an average of 10 pounds.
Founder, Chairman and Executive Creative Director for Hawthorne Direct, Timothy R. Hawthorne said, "We are pleased to be marketing a naturally safe solution to weight loss through DRTV. We have incredibly high expectations for the Nova Pharmaceutical's NxTrim campaign. The diet and weight loss category of direct response television has enjoyed phenomenal success and we believe that the DRTV world will respond favorably to NxTrim."
Nova has expressed its confidence in Hawthorne's ability to pair high quality infomercials with strategic media buys within all requirements of various Government regulatory authorities. "Hawthorne provides a complete package," says Mr. Mann. He adds, "they take all necessary steps to ensure success. The team involved with this project has extensive experience with promotions of this nature." Nova and Hawthorne plan to begin the testing of the infomercial in April of this year.
The Company will be developing a new web site specifically for the infomercial. The company has secured the domain www.nxtrim.com for direct e-commerce support. The web site will reflect the features of the infomercial with a secured on-line order page.
Nova is confident that it will be successful with the direct marketing campaign for NxTrim and plans to continue to support its retail channels of distribution. The Company believes that the increased exposure for NxTrim will generate increased movement through its current retail channels of distribution, as well as increasing the distribution for the product.
About Nova Pharmaceutical Inc
Nova Pharmaceutical Inc. is a publicly traded company on the OTC Bulletin Board (ticker symbol:NOVX). The company's patented weight loss product, NxTrim, achieved first year sales of $2,000,000, and is currently the number one selling diet aid in the California Drug class of trade according to data provided by Information Resources Inc.
Nova Pharmaceutical Inc. is the sole manufacturer, distributor, and marketer of Gold's Gym Nutrition supplements.
More information about the products and services of Nova Pharmaceutical Inc is available at the Company's web site www.novanx.com. The Company also hosts an informational web site for the Gold's Gym Nutrition line of products at www.goldsgymnutrition.com.
Certain statements in this release are "forward looking" statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
SOURCE: Nova Pharmaceutical Inc.
CONTACT: Ralph Mann, CEO & President, or Jim Ayres, Vice President & Secretary, firstname.lastname@example.org, both of Nova Pharmaceutical Inc., 888-495-NOVA (6682); or Joe Stapley of Travis Morgan Securities, 949-261-2906, for Nova Pharmaceutical Inc.